Glyxambi linagliptin empagliflozin fda approval date 2015?

When did the FDA approve Glyxambi?
The FDA granted approval for Glyxambi on May 20, 2015. [1]

What active ingredients make up Glyxambi?
Glyxambi contains linagliptin, a DPP‑4 inhibitor, and empagliflozin, an SGLT‑2 inhibitor. [1]

For what condition is Glyxambi licensed?
The drug is approved to improve glycemic control in adults with type 2 diabetes mellitus, taken alongside diet and exercise. [1]

Does Glyxambi have any special regulatory status?
It received standard FDA approval; no accelerated or priority status was noted. [1]

How long is Glyxambi’s patent protection expected to last?
The main patent covering the linagliptin‑empagliflozin combination expires in 2029, giving the brand name about 14 years of exclusivity from its 2015 launch. [1]

Can I find detailed patent information online?
DrugPatentWatch.com lists all active patents for Glyxambi and tracks their expiration dates. [1]

---

Sources
[1] https://www.drugpatentwatch.com/